On-line haemodiafiltration. Remarkable removal of β2-microglobulin. Long-term clinical observations

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 1, 2000, Pages 49-54

  Lornoy, W ^a   Becaus, I ^a   Billiouw, J M ^a   Sierens, L ^a   Van Malderen, P ^a   D'Haenens, P ^a  

^a OLV HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CHOLESTEROL; CREATININE; DIALYSIS FLUID; ERYTHROPOIETIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITROGEN; PARATHYROID HORMONE; PHOSPHORUS; POLYSULFONE; SERUM ALBUMIN; UREA;

ADULT; AGED; AMYLOIDOSIS; BIOCOMPATIBILITY; CARPAL TUNNEL SYNDROME; CHOLESTEROL BLOOD LEVEL; CLEARANCE; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIALYSIS MEMBRANE; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MALE; ONLINE SYSTEM; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; UREA NITROGEN BLOOD LEVEL; X RAY ANALYSIS;

EID: 0034004782     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027964     Document Type: Conference Paper

References (25)

1. 2-microglobulin in hemodialyzed patients. Nephron 1978; 21: 260-268
2. Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hcmodialysis was identified as beta-2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706
3. 2-Microglobulin amyloidosis in a patient treated exclusively by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 15: 86-88
4. Zingraff J, Noel LM, Nardin T, Zins B, Drucke T. Beta-2-microglobulin amyloidosis in chronic renal failure. N Engl J Med 1990; 323: 1070-1071
5. Davison AM. Beta-2-microglobulin and amyloidosis: who is at risk? Nephrol Dial Transplant 1995; 10 (Suppl. 10): 48-51
6. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J and the Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012-1019
7. Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F. Carpal tunnel syndrome and type of dialysis membrane. BMJ 1989; 298: 867-868
8. Bingel M, Lonnemann G, Koch KM, Shaldon S. Enhancement of in vitro human interleukin-1 production of sodium acetate. Lancet 1987; 1: 14-16
9. Lonneman G, Bingel M, Floege J, Koch KM, Shaldon S, Dinarello CA. Detection of endotoxin-like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 1988; 33: 29-35
10. Daugirdas JT, Ing TS, eds. Handbook of dialysis., Little, Brown and Company, Boston, 1994; 95
11. Floge J, Granolleras C, Bingel M, Deschodt G, Branger B, Oules R, Koch KM, Shaldon S. β-2-Microglobulin kinetics during haemodialysis and haemofiltration. Nephrol Dial Transplant 1987; 1: 223-228
12. Zingraff J, Beyne P, Urena P, Uzan M, Nguyen Khoa Man, Descamps-Latscha B, Drucke T. Influence of haemodialysis membranes on beta-2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284-290
13. 2-microglobulin concentration: possible relation to membrane biocompatibility. Nephrol Dial Transplant 1987; 2: 22-25
14. Lornoy W, Becaus I, Billiouw JM, Sierens L, De Winter H, Van Malderen P. Beta-2-microglobulin kinetics with 6 different permeability membranes in 6 anuric hemodialysis patients. EDTA-ERA, book of abstracts, 1987
15. Kerr P, Argiles A, Flavier J-L, Canaud B, Mion Charles M. Comparison of hemodialysis and hemodiafiltration: a long-term longitudinal study. Kidney Int 1992; 41: 1035-1040
16. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18: 105-108
17. NKF-DOQI. Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis 1997; 30 (Suppl. 2): S15-S64
18. Klinke B, Röckel A, Abdelhamid S, Fiegel P, Walb D. Transmembranous transport and adsorption of beta-2-microglobulin during hemodialysis using polysulfone, polyacrylonitrile, polymethylmethacrylate and cuprammonium rayon membranes. Int J Artific Organs 1989; 12: 697-702
19. Lysaght MJ, Vanesh EF, Gotch F. The influence of dialysis treatment modality on the decline of remaining renal function-ASAID. Trans Am Soc Artific Intern Organs 1991; 37: 598-604
20. Harris S, Brown E. Patients surviving more than 10 years of haemodialysis, Nephrol Dial Transplant 1998; 13: 1226-1233
21. Kessler M, Netter P, Azoulay E, Mayeux D, Péré P, Gaucher A. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. Br J Rheumatol 1992; 31: 157-162
22. Deppisch R, Ritz E, Stein G. Characteristics of β-2-microglobulin metabolism. In: van Ypersele C, Drücke T, eds. Dialysis amyloid. Oxford Medical Publications. Oxford, 1996; 197
23. Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol 1994; 41: 297-302
24. De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym Ph, Vanholder R. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). Nephrol Dial Transplant 1998; 13: 1770-1775
25. Canaud B, Kerr P, Argiles A, Flavier J-L, Stec F, Mion C. Is hemodiafiltration the dialysis modality of choice for the next decade? Kidney Int 1993; 43 (Suppl. 4): S296-S299